News: UCB S.A. (UCB.BR)
17 May 2013
Thu, Apr 25 2013
BRUSSELS, April 25 - Belgian drugmaker UCB had a difficult first quarter as cold spring weather in Europe meant fewer hay fever sufferers were buying its allergy medicines, it said on Thursday.
BRUSSELS, March 27 - Belgium-based drugmaker UCB said it has raised the maximum 250 million euros ($321.47 million) it was aiming for by selling a retail bond on the Brussels stock exchange to help refinance its debt.
BRUSSELS, March 19 - UCB S.A. : * UCB and Five Prime Therapeutics announce strategic discovery
BRUSSELS - Belgian pharmaceutical company UCB said on Tuesday its new epilepsy treatment Vimpat had produced promising results in a Phase III trial into its use without other drugs.
BRUSSELS - Belgian pharmaceutical company UCB has secured two regulatory clearances in Japan, further cementing its worldwide shift to a new generation of drugs.
Overview -- L'Union Canadienne (UC) is a Quebec-based property-casualty insurer. -- UC is considered strategically important to Royal & SunAlliance's (RSA) Canadian operations, which acquired UC on Oct. 1, 2012. -- UC's credit profile is also supported by good competitive position, good operating performance, and adequate capitalization. -- We are assigning our 'A-' financial strength and counterparty credit ratings to UC; the outlook is stable. Rating Action On Dec. 19,
- Don't Get Sacked by Parkinson's - Know the Full Range of Symptoms
- UCB SA/NV - Convocation to the Annual General Shareholders' meeting
- UCB and Emory partner to address pressing public health issues for people living with epilepsy
- VIMPAT (lacosamide) generates positive results in U.S. Phase 3 monotherapy study
- UCB SA/NV - Convocation to the Extraordinary General Meeting
- New Efforts Underway to Improve Care for Veterans with Epilepsy
- UCB, Inc. and Arthritis Foundation Partner to Celebrate the "Everyday Victories" of the Rheumatoid Arthritis Community
- UCB Announces New Data to Increase Understanding of Short- and Long-Term Clinical Profile of Antiepileptic Drug VIMPAT® (lacosamide)
- UCB Harnesses the Voices of the Crohn's Disease Community during Crohn's and Colitis Awareness Week
- UCB Announces New Data for VIMPAT® (lacosamide) at the 66th Annual Meeting of the American Epilepsy Society